Studies on the physical developer for use in immunohistochemistry.

Takita, Kaoruko; Shimada, Toshio; Kitamura, Hirokazu; Fujii, Shigetada; Nakamura, Mitsuo

doi:10.1267/ahc.23.647

Cited by 16 publications

(5 citation statements)

References 28 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…So far, Danscher's developer [2] has been widely utilized for histochemical studies, but it is not always stable. We thus made a new type of physical development method [9], which showed higher sensitivity and suppressed non-specific staining. This physical developer contains silver nitrate as silver supplier, bromohydroquinone as developing agent, and gum Arabic.…”

Section: Discussionmentioning

confidence: 99%

Distribution of Langerhans Cells in the Human Esophagus, as Revealed by Immunohistochemistry

Nagai

Noguchi

Fujiwara

et al. 2005

Acta Histochem. Cytochem

Self Cite

View full text Add to dashboard Cite

Our previous report illustrated that the epithelium of the human esophagus has numerous lymphocytes and Langerhans cells with Birbeck granules. In the present study, the distribution of Langerhans cells in the human esophagus was examined immunohistochemically. The human esophageal specimens were obtained by the surgery for esophageal carcinoma with informed consent. The tissue blocks were fixed with 10% formalin and embedded in paraffin. The thin sections were treated with anti-S-100 protein antibody, placed in IgG-gold (5 nm) solution as a second antibody, and then sensitized with the physical development method. The Langerhans cells, which showed a positive immunoreaction for the S-100, were distributed within the epithelium throughout the esophagus. Their distribution patterns differed according to the region of the esophagus. The Langerhans cells tended to increase in number as they moved further from the oral cavity toward the abdominal part. In this study, it was suggested that they played important roles in the immune response of the human esophagus.

show abstract

Section: Discussionmentioning

confidence: 99%

Distribution of Langerhans Cells in the Human Esophagus, as Revealed by Immunohistochemistry

Nagai

Noguchi

Fujiwara

et al. 2005

Acta Histochem. Cytochem

Self Cite

View full text Add to dashboard Cite

show abstract

“…Sections were immuno-stained with anitidesmin, and Cx40 and Cx43 antibodies, respectively, according to the immunogold-silver method. 34) For SEM, tissue blocks of the right auricle and BB were fixed in Karnovsky's fixative, and were treated with 2N NaOH for 2-3 h at room temperature in order to view the cytoskeleton of cardiac muscles. On the other hand, other tissue blocks were treated with 6N NaOH for 10 min at 61 C and then placed in an ultrasonic bath (38 kHz) for a supplementary 1 min to investigate the cytoarchitecture and intercalated disks.…”

Section: Methodsmentioning

confidence: 99%

Ultrastructure and Cytoarchitecture of Bachmann’s Bundle in the Mammalian Heart

Yamaguchi¹,

Yi²,

Tanaka³

et al. 2009

J Arrhythmia

Self Cite

View full text Add to dashboard Cite

Recently, the Bachmann's bundle (BB) has been examined in connection with atrial fibrillation. However, the morphological properties of the BB remain to be clarified.In this study, the BB in hearts of monkeys and sheep was investigated by immunohistochemistry, scanning (SEM) and transmission (TEM) electron microscopy.Immuno-histochemically, BB myocytes showed a strong positive reaction for desmin antibody and that connexin (Cx) 40 and Cx43 were distributed at the intercalated disks. BB myocytes were characterized by a dense network of intermediate filaments which enveloped nucleus, myofibrils and mitochondria, respectively. The intercalated disks showed an irregular stair-like profile. Microprojections on the steps were smaller in number and larger in size than those in auricular myocytes.In conclusion, BB myocytes were different ultrastructurally from auricular myocytes, showing morphological properties of the conduction system. (J Arrhythmia 2009; 25: 24-31)

show abstract

“…Heart and kidney obtained from the TgM/KO mouse treated with DGJ at 0.5 mM concentration in drinking water for 2 weeks were fixed in 4% paraformaldehyde/phosphate-buffered saline, embedded in paraffin, and sectioned at 4-m thickness. The paraffin section was stained by the immunogold silver technique described by Takita et al (1990). In brief, binding of the anti-␣-Gal A polyclonal antibody to sections was detected using goat anti-rabbit IgG gold (particle size, 5 nm) (Janssen Pharmaceuticals, Antwerp, Belgium), followed by developer solutions (10% gum Arabic aqueous solution containing 0.1% silver nitrate, 0.6% bromohydroquinone, and 1% citric acid).…”

Section: Methodsmentioning

confidence: 99%

Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease

Ishii

Chang²,

Yoshioka³

et al. 2008

J Pharmacol Exp Ther

Self Cite

View full text Add to dashboard Cite

Fabry disease is an inborn error of glycosphingolipid metabolism caused by deficiency of ␣-galactosidase A (␣-Gal A) activity. It has been shown that protein misfolding is primarily responsible for the enzyme deficiency in a large proportion of mutations identified in Fabry patients with residual enzyme activity, and 1-deoxygalactonojirimycin (DGJ) can effectively increase the residual enzyme activity in cultured patient's cells. Herein, we demonstrate the preclinical efficacy and safety of DGJ in transgenic mice that express human mutant ␣-Gal A activity. ␣-Gal A activity in heart, kidney, spleen, and liver was increased dose-and time-dependently. The mutant ␣-Gal A was increased in cardiomyocytes and distal convoluted tubules of the transgenic mice in a null background after 2 weeks of DGJ treatment. Globotriaosylceramide storage was remarkably reduced in kidney of mice after a 4-week treatment at a dosage of approximately 3 mg/kg body weight/day. The half-life of DGJ was less than 1 day in all major issues and that of the enzyme synthesized during the DGJ treatment period was approximately 4 days. No abnormality of blood chemistry and pathological tissue damage was found in mice treated with DGJ at ϳ30 mg/kg body weight/day for 9 weeks. Furthermore, no change was observed in appearance, growth, fertility, and life span in mice during a 2-year period of continuous administration of DGJ at the effective dosage. These preclinical results indicate that DGJ is effective in restoring mutant enzyme activity in tissues and reversing substrate storage in kidney and is well tolerated in mice.

show abstract

Studies on the physical developer for use in immunohistochemistry.

Cited by 16 publications

References 28 publications

Distribution of Langerhans Cells in the Human Esophagus, as Revealed by Immunohistochemistry

Distribution of Langerhans Cells in the Human Esophagus, as Revealed by Immunohistochemistry

Ultrastructure and Cytoarchitecture of Bachmann’s Bundle in the Mammalian Heart

Preclinical Efficacy and Safety of 1-Deoxygalactonojirimycin in Mice for Fabry Disease

Contact Info

Product

Resources

About